Watanabe Jun, Kotani Kazuhiko
Center for Community Medicine, Jichi Medical University, Shimotsuke-City, Japan.
Vasc Health Risk Manag. 2020 Apr 17;16:149-155. doi: 10.2147/VHRM.S245829. eCollection 2020.
The importance of management of metabolic syndrome (MetS) for risk reduction of cardiovascular disease (CVD) has been recognized worldwide. Because of the comparatively unique characteristics of bodily figure/obesity and incident CVD in Japan, the relevance of MetS on CVD can be still discussed among Japanese people. The present study aimed to review briefly the relationship of MetS with CVD morbidity/mortality among general Japanese people.
Population-based prospective cohort studies evaluating the predictive value of MetS on CVD morbidity/mortality via a PubMed search up to 2019 were summarized.
We identified two studies on morbidity that reported MetS to predict CVD morbidity. We identified three studies on mortality, and these studies showed an increased direction of hazard ratio (HR) of CVD mortality, while one study reported an insignificant prediction of MetS for CVD mortality. In the meta-analysis method, MetS significantly predicted CVD morbidity (HR=1.71 [95% confidence interval=1.34-2.18] in men and HR=1.89 [95% confidence interval=1.45-2.46] in women) as well as CVD mortality (HR=1.68 [95% confidence interval=1.37-2.06] in men and HR=1.73 [95% confidence interval=1.39-2.15] in women).
Among general Japanese people, MetS can be a positive predictor of CVD morbidity/mortality. Since the studies are limited, more research is needed to establish the findings.
代谢综合征(MetS)管理对于降低心血管疾病(CVD)风险的重要性已在全球范围内得到认可。由于日本人体型/肥胖及CVD发病情况具有相对独特的特征,MetS与CVD之间的相关性在日本人中仍存在争议。本研究旨在简要回顾日本普通人群中MetS与CVD发病率/死亡率之间的关系。
通过检索截至2019年的PubMed数据库,总结基于人群的前瞻性队列研究,评估MetS对CVD发病率/死亡率的预测价值。
我们确定了两项关于发病率的研究,报告称MetS可预测CVD发病率。我们确定了三项关于死亡率的研究,这些研究显示CVD死亡率的风险比(HR)呈上升趋势,而一项研究报告称MetS对CVD死亡率的预测无统计学意义。在荟萃分析方法中,MetS显著预测CVD发病率(男性HR = 1.71 [95%置信区间 = 1.34 - 2.18],女性HR = 1.89 [95%置信区间 = 1.45 - 2.46])以及CVD死亡率(男性HR = 1.68 [95%置信区间 = 1.37 - 2.06],女性HR = 1.73 [95%置信区间 = 1.39 - 2.15])。
在日本普通人群中,MetS可能是CVD发病率/死亡率的阳性预测指标。由于研究有限,需要更多研究来证实这些发现。